ChemPartner Immunologists specialize in T cell biology and other primary immune assays. We use readouts from proliferation, ELISA, Luminex as well as flow cytometry analyses to help our global pharma and biotech partners with drug discovery for cancer immunotherapy and autoimmune diseases.
The efficacy and Mode of Action (MOA) of client compounds are further characterized by our extensive array of in vivo pharmacodynamics (PD) and pharmacological models of human diseases, including rheumatoid arthritis (RA), multiple sclerosis, asthma, inflammatory bowel diseases, skin inflammatory diseases, respiratory inflammation and syngeneic tumor models. We complement normal efficacy studies with additional imaging studies, including microCT of bone mineral density for evaluating drugs that are used to treat RA bone erosion, together with collecting synovial fluid to analyze cytokine content as surrogate markers.
Our inflammatory PD models include LPS-induced TNFα release in rodents or monkeys, skin DTH, and air pouch assay. Immune profiling of bronchoalveolar lavage and of isolated draining lymph nodes or inflamed tissues (FACS or IHC) provides opportunities for MOA understanding and biomarker discovery.